A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Participants With Rheumatoid Arthritis
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. Researchers are doing this trial to learn if a trial medicine called MK-8690 can treat symptoms of active RA in people who are taking MTX.
The goal of this study is to learn if MK-8690 works better than placebo to improve RA symptoms.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a clinical diagnosis of rheumatoid arthritis (RA) and fulfillment of 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria
- Has active disease defined as ≥6 tender joints (based on 68 joints) and ≥6 swollen joints (based on 66 joints)
- Has current treatment with oral or parenteral methotrexate (MTX) therapy
- Has history of one of the following: a) biologic disease-modifying antirheumatic drug (bDMARD) naïve, or b) bDMARD-inadequate response (IR)/intolerant up to a maximum of 1 class of bDMARD
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than RA (such as, but not limited to, psoriatic arthritis, systemic lupus erythematosus, gout, systemic sclerosis, myositis, pseudogout, etc.), or any other condition that may interfere with the assessment of RA
- Has a transplanted organ and requires continued systemic immunosuppression
- Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for <5 years before randomization
- Is known to be infected with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus
- Has an active infection
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Period 1: MK-8690
Participant will receive MK-8690 subcutaneous (SC) for 12 weeks |
Solution for SC injection
Inne nazwy:
Background therapy - variable dose strength with route of administration per approved product label |
|
Komparator placebo: Period 1: Placebo
Participant will receive placebo SC for 12 weeks |
Background therapy - variable dose strength with route of administration per approved product label Solution for SC injection |
|
Eksperymentalny: Extension Period
After completing Period 1 participants will receive MK-8690 SC for 40 weeks. |
Solution for SC injection
Inne nazwy:
Background therapy - variable dose strength with route of administration per approved product label |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12
Ramy czasowe: Week 12
|
ACR response is a well-established composite measure used in clinical trials to evaluate clinical response in rheumatoid arthritis (RA). ACR50 response is defined as 50% or greater improvement in tender joint count (TJC) based on 68 joints, swollen joint count (SJC) based on 66 joints, and ≥3 of the 5 remaining components of Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment of Disease Activity (PGA), Patient Global Assessment of Disease Activity (PtGA), Patient Assessment of Pain Severity, and high-sensitivity C-reactive protein (hsCRP). ACR50 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 50% improvement in the composite measure. The percentage of participants achieving ACR50 at Week 12 will be presented. |
Week 12
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Ramy czasowe: Up to approximately 70 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience 1 or more AEs will be presented. |
Up to approximately 70 weeks
|
|
Number of Participants Who Discontinue Study Intervention Due to an AE
Ramy czasowe: Up to approximately 48 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be presented. |
Up to approximately 48 weeks
|
|
Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12
Ramy czasowe: Week 12
|
ACR20 response is defined as 20% or greater improvement in TJC based on 68 joints, SJC based on 66 joints, and ≥3 of the 5 remaining components of HAQ-DI, PGA, PtGA, Patient Assessment of Pain Severity, and hsCRP. ACR20 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 20% improvement in the composite measure. The percentage of participants achieving ACR20 at Week 12 will be presented. |
Week 12
|
|
Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12
Ramy czasowe: Week 12
|
ACR70 response is defined as 70% or greater improvement in TJC based on 68 joints, SJC based on 66 joints, and ≥3 of the 5 remaining components of HAQ-DI, PGA, PtGA, Patient Assessment of Pain Severity, and hsCRP. ACR70 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 70% improvement in the composite measure. The percentage of participants achieving ACR70 at Week 70 will be presented. |
Week 12
|
|
Percentage of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP) at Week 12
Ramy czasowe: Week 12
|
The DAS28-CRP is a continuous composite measure of RA activity that includes the following components:
|
Week 12
|
|
Change from Baseline in DAS28-CRP
Ramy czasowe: Baseline and at designated timepoints up to Week 52
|
The DAS28-CRP is a continuous composite measure of RA activity that includes the following components:
|
Baseline and at designated timepoints up to Week 52
|
|
Percentage of Participants Achieving LDA based on DAS28-CRP
Ramy czasowe: At designated timepoints up to Week 52
|
The DAS28-CRP is a continuous composite measure of RA disease activity that includes the following components:
|
At designated timepoints up to Week 52
|
|
Percentage of Participants Achieving Clinical Remission Based on DAS28-CRP
Ramy czasowe: At designated timepoints assessed up to Week 52
|
The DAS28-CRP is a continuous composite measure of RA disease activity that includes the following components:
|
At designated timepoints assessed up to Week 52
|
|
Change From Baseline in the HAQ-DI Score
Ramy czasowe: Baseline and Week 12
|
HAQ-DI is measure of physical function in RA clinical trials and is a 20-item questionnaire completed by the participant. The measure includes 8 domains assessing "dressing and grooming," "arising," "eating," "walking," "hygiene," "reach," "grip," and "activities." Participants respond on a 4-point scale ranging from 0 = "without ANY difficulty" to 3 = "UNABLE to do." The measure also captures the use of aids or devices and need for help from another person. The overall disability score is a summation of the highest score from each domain divided by the number of domains completed and ranges from 0 to 3 (worst disability). Clinically meaningful improvement in HAQ-DI for RA has been determined to be ≥0.22 points. The change from Baseline to Week 12 in the HAQ-DI will be presented. |
Baseline and Week 12
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Medical Director, Merck Sharp & Dohme LLC
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu mięśniowo-szkieletowego
- Artretyzm
- Choroby stawów
- Choroby reumatyczne
- Choroby tkanki łącznej
- Choroby Autoimmunologiczne
- Choroby układu odpornościowego
- Choroby skóry i tkanki łącznej
- Zapalenie stawów, reumatoidalne
- Związki heterocykliczne
- Związki heterocykliczne, 2-ring
- Związki heterocykliczne, sterowanie stopieniem
- Pterins
- Perydyny
- Aminopterina
- Metotreksat
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 8690-004
- MK-8690-004 (Inny identyfikator: MSD)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .